Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Adv Exp Med Biol ; 1412: 225-235, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37378770

RESUMO

BACKGROUND: COVID-19 disease caused by the SARS-CoV-2 virus can lead to an acute respiratory illness with a high hospitalization and mortality risk. Therefore, prognostic indicators are essential for early interventions. As a component of complete blood counts, the coefficient of variation (CV) of red blood cell distribution width (RDW) reflects cellular volume variations. It has been shown that RDW is associated with increased mortality risk in a wide range of diseases. This study aimed to determine the relationship between RDW and mortality risk in COVID-19 patients. METHODS: This retrospective study was performed on 592 patients admitted to hospital between February 2020 and December 2020. Patients were divided into low and high RDW groups and the relationship between RDW and mortality, intubation, admission to intensive care unit (ICU), and need for oxygen therapy was investigated. RESULTS: The mortality rate in the low RDW group was 9.4%, while that in the high group was 20% (p < 0.001). Also, ICU admission in the low group was 8%, whereas this was 10% in the high RDW group (p = 0.040). The results of the Kaplan-Meyer curve showed that the survival rate was higher in the low group compared to the high RDW group. Cox results in the crude model showed that higher RDW values were directly related to increased mortality, although this was not significant after adjustment for other covariates. CONCLUSION: The results of our study reveal that high RDW is associated with increased hospitalization and risk of death and that RDW may be a reliable indicator of COVID-19 prognosis.


Assuntos
COVID-19 , Índices de Eritrócitos , Humanos , Prognóstico , Estudos Retrospectivos , COVID-19/terapia , SARS-CoV-2 , Hospitalização , Unidades de Terapia Intensiva
2.
Curr Atheroscler Rep ; 22(5): 19, 2020 05 26.
Artigo em Inglês | MEDLINE | ID: mdl-32458165

RESUMO

PURPOSE OF REVIEW: In this review, we discuss the evidence supporting the effects of statins on mast cells (MCs) in atherosclerosis and their molecular mechanism of action. RECENT FINDINGS: Statins or HMG-CoA reductase inhibitors are known for their lipid-lowering properties and are widely used in the prevention and treatment of cardiovascular diseases. There is growing evidence that statins have an inhibitory effect on MCs, which contributes to the pleiotropic effect of statins in various diseases. MCs are one of the crucial effectors of the immune system which play an essential role in the pathogenesis of multiple disorders. Recent studies have shown that MCs are involved in the development of atherosclerotic plaques. MCs secrete various inflammatory cytokines (IL-6, IL4, TNF-α, and IFNγ) and inflammatory mediators (histamine, tryptase, proteoglycans) after activation by various stimulants. This, in turn, will exacerbate atherosclerosis. Statins suppress the activation of MCs via IgE inhibition which leads to inhibition of inflammatory mediators and cytokines which are involved in the development and progression of atherosclerosis. In keeping with this evidence presented here, MCs can be considered as one of the therapeutic targets for statins in the treatment of atherosclerosis.


Assuntos
Aterosclerose/tratamento farmacológico , Aterosclerose/fisiopatologia , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Mastócitos/efeitos dos fármacos , Animais , Degranulação Celular/efeitos dos fármacos , Citocinas/metabolismo , Liberação de Histamina/efeitos dos fármacos , Humanos , Mastócitos/imunologia , Mastócitos/metabolismo , Inibidores de Metaloproteinases de Matriz/farmacologia , Inibidores de Metaloproteinases de Matriz/uso terapêutico , Inibidores de Fosfolipase A2/farmacologia , Inibidores de Fosfolipase A2/uso terapêutico , Placa Aterosclerótica/fisiopatologia , Receptores de LDL/agonistas , Receptores Toll-Like/antagonistas & inibidores , Receptores Toll-Like/metabolismo
3.
J Cell Physiol ; 234(8): 12404-12414, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-30609023

RESUMO

Leukemia comprises a group of hematological malignancies responsible for 8% of all cancers and is the most common cancer in children. Despite significant improvements in leukemia treatment, the efficacy of conventional chemotherapeutic agents is low and the disease carries a poor prognosis with frequent relapses and high mortality. Curcumin is a yellow polyphenol compound with diverse pharmacological actions including anticancer, antioxidant, antidiabetic, anti-inflammatory, immunomodulatory, hepatoprotective, lipid-regulating, antidepressant, and antiarthritic. Many cellular and experimental studies have reported the benefits of curcumin in treating leukemia. Curcumin's anticancer effects are exerted via various mechanisms. Here, we review the effects of curcumin on various types of leukemia whilst considering its mechanisms of action.


Assuntos
Antineoplásicos/uso terapêutico , Curcumina/uso terapêutico , Leucemia/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico , Criança , Humanos , Resultado do Tratamento
4.
J Caring Sci ; 12(2): 79-83, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37469752

RESUMO

Introduction: One of the most important strategies to control COVID-19 pandemic is vaccination. Effective vaccination coverage is necessary to control this pandemic. Therefore, in this study we investigated acceptance of COVID-19 vaccine and associated factors among Iranian population. Methods: A cross-sectional study conducted through Pors Line in South Khorasan Province of Iran. 1043 people participated in this study. Results were analyzed with SPSS software version 13. Results: 85.2% of the participants wanted to receive the vaccine. Vaccine acceptance was higher in participants that were over 41 years old. Moreover, rate of vaccine acceptance was higher in men than women. Major concern about vaccination was fear of its side effects. Vaccine acceptance increased with increasing education level. Conclusion: Results of this study showed that one of the most important reasons for vaccine rejection is the fear of vaccine side effects.

5.
J Educ Health Promot ; 12: 405, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38333152

RESUMO

BACKGROUND: Widespread vaccination coverage in the shortest time is one of the most effective ways for controlling the COVID-19 pandemic. Factors affecting people's intention to get the COVID-19 vaccine are of great importance. The present study aimed to investigate the predictors of the intention to receive the Covid-19 vaccine based on the constructs of the health belief model (HBM) and theory of planned behavior (TPB) in South Khorasan Province. MATERIALS AND METHODS: In this cross-sectional-analytical study, 320 people over 18 years in South Khorasan province were randomly selected by cluster sampling method in 2021. The data was collected by a researcher-made questionnaire, including demographic information (9 questions), and the constructs of the health belief model (19 questions), and the theory of planned behavior (13 questions), using the self-report method. Finally, data were analyzed using t-test, ANOVA, linear regression, and Pearson correlation tests. RESULTS: The mean age of the study participants was 36.57 ± 11.56 with a range of 18-66 years. In the regression model, perceived susceptibility (ß = 0.247, P = 0.003), perceived severity (ß = 0.247, P = 0.003) from HBM, attitude (ß = 0.247, P = 0.003), and perceived behavioral control (ß = 0.247, P = 0.003) from TPB were significant predictors of the intention to get the Covid-19 vaccine. The constructs of the two models were able to explain 33% of the variance of the intention to receive the Covid-19 vaccine. CONCLUSIONS: The study findings reveal that HBM and TPB can predict factors affecting an individual's intention to receive the vaccine. The results can be utilized to design interventions with the aim of increasing vaccine uptake.

6.
Iran J Allergy Asthma Immunol ; 21(3): 344-354, 2022 Jun 18.
Artigo em Inglês | MEDLINE | ID: mdl-35822684

RESUMO

Neutropenia congenita grave (SCN) is a rare disease with a genetically and clinically heterogeneous nature, usually diagnosed in childhood, with an elevated risk of infections such as otitis, skin infections, pneumonia, deep abscesses, and septicemia. Patients with SCN also have an increased risk of leukemia, and mutations in the ELANE and the HAX1 genes have been observed in those patients. This study was conducted to genetically screen six Iranian families with SCN who have at least one affected person. In the first step, all exons and intron boundaries of ELANE and HAX1 genes were sequenced in probands. Cases with no pathogenic mutations were tested through whole-exome sequencing (WES). Analysis showed five different variants in ELANE (c.377 C>T), HAX1 (c.130_131 insA), HYOU1 (c.69 G>C and c.2744 G>A) and SHOC2 (c.4 A>G) genes in four families. We found that two out of six families had mutations in ELANE and HAX1 genes. Moreover, we found two novel mutations at the HYOU1 gene that had not previously been reported, as well as a pathogenic mutation at SHOC2 with multiple phenotypes, that will contribute to determining the genetic basis for SCN. Our study revealed that WES could help diagnose SCN, improve the classification of neutropenia, and rule out other immunodeficiencies such as autoimmune neutropenia, primary immunodeficiency diseases, and inherited bone marrow failure syndromes.


Assuntos
Proteínas Adaptadoras de Transdução de Sinal , Síndrome Congênita de Insuficiência da Medula Óssea , Peptídeos e Proteínas de Sinalização Intracelular , Elastase de Leucócito , Neutropenia , Proteínas Adaptadoras de Transdução de Sinal/genética , Síndrome Congênita de Insuficiência da Medula Óssea/genética , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/genética , Irã (Geográfico)/epidemiologia , Elastase de Leucócito/genética , Neutropenia/congênito , Neutropenia/diagnóstico , Neutropenia/genética
7.
Front Cardiovasc Med ; 9: 820260, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35282379

RESUMO

Background: Coronavirus disease 2019 (COVID-19) might affect everyone, but people with comorbidities such as hypertension and cardiovascular disease (CVD) may often have more severe complications and worse outcomes. Although vaccinations are being performed worldwide, it will take a long time until the entire population of the world is vaccinated. On the other hand, we are witnessing the emergence of new variants of this virus. Therefore, effective therapeutic approaches still need to be considered. Statins are well-known lipid-lowering drugs, but they have also anti-inflammatory and immunomodulatory effects. This study aimed to investigate the effects of statins on the survival of COVID-19 hospitalized patients. Methods: This retrospective study was performed on 583 patients admitted to a highly referenced hospital in Tabas, Iran, between February 2020 and December 2020. One hundred sixty-two patients were treated with statins and 421 patients were not. Demographic information, clinical signs, and the results of laboratory, and comorbidities were extracted from patients' medical records and mortality and survival rates were assessed in these two groups. Results: The results of the Cox crude regression model showed that statins reduced mortality in COVID-19 patients (HR = 0.56, 95% CI: 0.32, 0.97; p = 0.040), although this reduction was not significant in the adjusted model (HRs=0.51, 95%CI: 0.22, 1.17; p = 0.114). Using a composite outcome comprising intubation, ICU admission, and mortality, both crude (HR = 0.43; 95% CI: 0.26, 0.73; p = 0.002) and adjusted (HR = 0.57; 95% CI: 0.33, 0.99; p = 0.048) models suggested a significant protective effect of statin therapy. Conclusion: Due to anti-inflammatory properties of statins, these drugs can be effective as an adjunct therapy in the treatment of COVID-19 patients.

8.
Iran J Basic Med Sci ; 24(12): 1643-1649, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-35432798

RESUMO

Objectives: Despite advances in the treatment of adult T-cell leukemia/lymphoma (ATLL), the survival rate of this malignancy remains significantly low. Auraptene (AUR) is a natural coumarin with broad-spectrum anticancer activities. To introduce a more effective therapeutic strategy for ATLL, we investigated the combinatorial effects of AUR and arsenic trioxide (ATO) on MT-2 cells. Materials and Methods: The cells were treated with different concentrations of AUR for 24, 48, and 72 hr, and viability was measured by alamarBlue assay. Then, the combination of AUR (20 µg/ml) and ATO (3 µg/ml) was administrated and the cell cycle was analyzed by PI staining followed by flow cytometry analysis. In addition, the expression of NF-κB (REL-A), CD44, c-MYC, and BMI-1 was evaluated via qPCR. Results: Assessment of cell viability revealed increased toxicity of AUR and ATO when used in combination. Our findings were confirmed by accumulation of cells in the sub G1 phase of the cell cycle and significant down-regulation of NF-κB (REL-A), CD44, c-MYC, and BMI-1. Conclusion: Obtained findings suggest that combinatorial use of AUR and ATO could be considered for designing novel chemotherapy regimens for ATLL.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa